The intricate regulatory roles of DRG2, TRAPPC4, HIP1R, and CMTM6 in PD-L1 trafficking and stability present compelling opportunities for therapeutic intervention to enhance anti-tumor immunity. Here, DRG2 is linked to neoplasm.